+43 (0)2236 45013
Jacques van Meel
Professional Expertise Jacques C.A. van Meel
Academic education in Medicinal Chemistry (MSc at Vrije University, Amsterdam) and Pharmacy (M.Pharm at University of Amsterdam, Amsterdam)), Pharmacist certificate, and PhD degree with highest honour in Pharmacology (University of Amsterdam). Twenty-six years experience in pharmaceutical drug development at Boehringer Ingelheim in Biberach/Riss (Germany) and Vienna (Austria).
Broad basic research and compound development experience which includes target identification, target validation, HTS, lead identification and optimization, and candidate selection as well as preclinical support in Cardiovascular Research (indications Heart Failure, Hypertension) and Oncology Research. Comprehensive people, financial and research management experience.
Significant contribution to bringing two compounds for cardiovascular indications on the market (Micardis®; Acardi®/Vetmedin®), and a significant contribution for bringing three compounds in pivotal clinical stage II/III studies in oncology. These are Tovok (BIBW2992), an irreversible EGFR/Her2 inhibitor and Vargatef (BIBF1120), a VEGFR2 inhibitor in pivotal phase III studies. The Plk1 inhibitory compound BI 6727 is in a broad clinical phase II program for various indications in oncology.
The first demonstration of a licensing agreement is the establishment of a collaboration between Priaxon (Münich, Germany) and Boehringer Ingelheim (Vienna, Austria) in December 2009 for the identification and development of innovative oncology compounds (see Priaxon Website).
|Copyright © 2010 Jacques van Meel, All rights reserved.|